Kenji Hikita

Part of MediBIC Group, Animal Stemcell KK engages in research and development, and production of animal stem cells and regenerative medicine. The company is based in Koganei, Japan. Animal Stemcell KK was acquired by MediBIC Group from Resort & Medical Co., Ltd. on October 08, 2013 for $3.02 million.

Part of MediBIC Group, MediBIC KK develops genomic medicines. The company is based in Tokyo, Japan. The Japanese company was founded by Yasuhiro Hashimoto.

Site Quality Co., Ltd. provides consulting services to medical institutions. It offers informed consent acquisition assistance, patient schedule administration, hospital data collection management, time monitoring, case report form preparation support, document creation assistance, and clinical research coordination. The company was founded in November 2003 and is headquartered in Hachioji, Japan.

Part of MediBIC Group, Animal Stemcell KK engages in research and development, and production of animal stem cells and regenerative medicine. The company is based in Koganei, Japan. Animal Stemcell KK was acquired by MediBIC Group from Resort & Medical Co., Ltd. on October 08, 2013 for $3.02 million.

Part of MediBIC Group, MediBIC KK develops genomic medicines. The company is based in Tokyo, Japan. The Japanese company was founded by Yasuhiro Hashimoto.

Part of MediBIC Group, MediBIC KK develops genomic medicines. The company is based in Tokyo, Japan. The Japanese company was founded by Yasuhiro Hashimoto.

Site Quality Co., Ltd. provides consulting services to medical institutions. It offers informed consent acquisition assistance, patient schedule administration, hospital data collection management, time monitoring, case report form preparation support, document creation assistance, and clinical research coordination. The company was founded in November 2003 and is headquartered in Hachioji, Japan.

Site Quality Co., Ltd. provides consulting services to medical institutions. It offers informed consent acquisition assistance, patient schedule administration, hospital data collection management, time monitoring, case report form preparation support, document creation assistance, and clinical research coordination. The company was founded in November 2003 and is headquartered in Hachioji, Japan.

Ambicion KK is a company based in Tokyo, Japan that focuses on developing novel cancer immunotherapies and allergy treatments. The Japanese company specializes in creating drugs that target NKT cells and promoting cancer immunotherapy that targets NKT cells, which is not covered by insurance. The company was founded in 2015, and the CEO is Kenji Suzuki.